Monday, May 21, 2012
BioCentury's 10th annual
European Iceberg Survey foresees diverging capital needs for private and public
clinical-stage companies over the next three years.
Overall, the region's projected
financing demand to support operations through the end of 2014 has reached an
all-time high of $5.7 billion, up 6% from $5.4 billion in last year's survey (see
"Europe's Total Demand").